Travere Therapeutics, Inc. (TVTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 114,449 | 81,732 | 62,898 | 54,116 |
| Selling, general and administrative | 76,216 | 72,838 | 65,619 | 64,776 |
| Restructuring | - | - | 123 | 653 |
| Research and development | 49,362 | 46,889 | 51,679 | 54,330 |
| Cost of goods sold | 1,521 | 4,679 | 1,626 | 2,061 |
| In-process research and development | - | - | - | - |
| Total operating expenses | 127,099 | 124,406 | 119,047 | 121,820 |
| Operating loss | -12,650 | -42,674 | -56,149 | -67,704 |
| Other (expense) income, net | -526 | 549 | 520 | -3,495 |
| Interest income | 3,287 | 3,795 | 3,570 | 4,420 |
| Interest expense | 2,846 | 2,857 | 2,777 | 2,788 |
| Total other (expense) income, net | -85 | 1,487 | 1,313 | -1,863 |
| Loss from continuing operations before income tax provision | -12,735 | -41,187 | -54,836 | -69,567 |
| Income tax provision on continuing operations | 20 | 39 | -84 | 85 |
| Loss from continuing operations, net of tax | -12,755 | -41,226 | -54,752 | -69,652 |
| Loss from discontinued operations, net of tax | - | - | -59 | -757 |
| Net loss | -12,755 | -41,226 | -54,811 | -70,409 |
| Unrealized loss on marketable debt securities | -237 | -77 | 1,421 | -146 |
| Foreign currency translation gain (loss) | 268 | -686 | -803 | 404 |
| Comprehensive loss | -12,724 | -41,989 | -54,193 | -70,151 |
| Net loss per common share, basic (in dollars per share) | -0.14 | -0.47 | -0.7 | -0.91 |
| Net loss per common share, diluted (in dollars per share) | -0.14 | -0.47 | -0.7 | -0.91 |
| Weighted average common shares outstanding, basic (in shares) | 88,945,624 | 88,355,973 | 77,779,379 | 77,500,245 |
| Weighted average common shares outstanding, diluted (in shares) | 88,945,624 | 88,355,973 | 77,779,379 | 77,500,245 |